NSCLC — Expanded Access Programs
Overview
Right2Hope maintains a directory of 48 expanded access programs, clinical trials, and compassionate use pathways listed for NSCLC. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with nsclc programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 14 programs are currently active or recruiting, with the remaining 34 in other lifecycle stages. Sponsors actively running programs in this area include Memorial Sloan Kettering Cancer Center, A2 Biotherapeutics Inc., ImmVira Pharma Co. Ltd, Jacobio Pharmaceuticals Co., Ltd., Pfizer, and others.
By recruiting status
Snapshot of where every NSCLC program currently sits in its lifecycle.
- Active / Recruiting14
- Inactive34
Top sponsors
Organisations running the most NSCLC programs in the directory.
- Memorial Sloan Kettering Cancer Center6 programs
- A2 Biotherapeutics Inc.2 programs
- ImmVira Pharma Co. Ltd2 programs
- Jacobio Pharmaceuticals Co., Ltd.2 programs
- Pfizer2 programs
- Revolution Medicines, Inc.2 programs
- 7 Hills Pharma, LLC1 program
- Albert Einstein College of Medicine1 program
- Alliance Foundation Trials, LLC.1 program
- Apollomics Inc.1 program
NSCLC programs (48)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on BIO 300 and Chest Radiation Therapy for People with Non-Small Cell Lung Cancer and Interstitial Lung Disease — Memorial Sloan Kettering Cancer Center
- Study on REGN5093 for Treating Advanced Non-Small Cell Lung Cancer with MET Alterations — Regeneron Pharmaceuticals
- Study on the Safety and Effectiveness of A2B530 CAR T-Cell Therapy for Solid Tumors with CEA Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
- Continued Access Study for Patients Benefiting from Avelumab in Closing Pfizer-Sponsored Studies — Pfizer
- Study on Whether Durvalumab and Radiation Therapy Can Slow Down Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
- Phase 1/2 Study of S241656 for Cancers with Specific RAS/MAPK Mutations — Institut de Recherches Internationales Servier
- Study on Using Stereotactic Body Radiation Therapy (SBRT) for Patients with Metastatic Breast and Lung Cancers — Memorial Sloan Kettering Cancer Center
- Study on Reduced Chemotherapy and Immunotherapy for Older Adults with Advanced Non-Small Cell Lung Cancer — Virginia Commonwealth University
- Study on Daraxonrasib for Previously Treated Patients with RAS Mutated Non-Small Cell Lung Cancer (NSCLC) — Revolution Medicines, Inc.
- Study of LP-184 for Patients with Advanced Solid Tumors — Lantern Pharma Inc.
- Study on RAS(ON) Inhibitors with Ivonescimab for Patients with Solid Tumors — Revolution Medicines, Inc.
- Study on D-1553 for Patients with Advanced Solid Tumors — InventisBio Co., Ltd
- Study on the Safety and Effectiveness of TNG462 Combination Therapy in Pancreatic and Lung Cancer Patients — Tango Therapeutics, Inc.
- Study on Thoracic Radiotherapy and PD-1 and LAG-3 Inhibition for Locally Advanced Non-Small Cell Lung Cancer — Albert Einstein College of Medicine
- Study on Intratumoral T3011 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — ImmVira Pharma Co. Ltd
- Study on BA3071 for Patients with Solid Tumors — BioAtla, Inc.
- Phase 2 Study of Adding Vitamin C to Chemotherapy and Radiation for Non-Small Cell Lung Cancer — Joseph J. Cullen, MD, FACS
- Phase 2 Study of EIK1001 with Pembrolizumab and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer — Eikon Therapeutics
- Study on the Safety and Effectiveness of HB0036 for Advanced Solid Tumors — Shanghai Huaota Biopharmaceutical Co., Ltd.
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — Merus N.V.
- Study on Local Ablative Therapy for People with Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
- Study Comparing Ociperlimab and Tislelizumab with Pembrolizumab for Untreated Lung Cancer — BeiGene
- Study on Oral Alintegimod with Ipilimumab and Nivolumab for Cancer Treatment — 7 Hills Pharma, LLC
- Study on Targeted Radiation Therapy for People with Metastatic Non-Small Cell Lung Cancer (NSCLC) — Memorial Sloan Kettering Cancer Center
- Study on the Safety and Effectiveness of CFT1946 Alone and in Combination for BRAF V600 Mutant Solid Tumors — C4 Therapeutics, Inc.
- Study on the Safety and Effectiveness of A2B694 CAR T-Cell Therapy for Solid Tumors with MSLN Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
- Study on Adagrasib and SRS for Patients with KRAS G12C-Mutated Lung Cancer with Untreated Brain Metastases — Ryan Gentzler, MD
- Study on Cisplatin-based Chemotherapy and Atezolizumab for Certain Stages of Resected Non-small Cell Lung Cancer (NSCLC) and Monitoring Circulating Tumor DNA — Nasser Hanna
- Study on Anti-PD-1 Antibody with Metabolic Modulator for Treating Solid Tumors — Dan Zandberg
- Study on APL-101 for Treating Advanced Solid Tumors with Specific Genetic Changes — Apollomics Inc.
- Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC — Alliance Foundation Trials, LLC.
- Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements — Joshua Palmer
- Study on the Duration of PD-1/PD-L1 Inhibitor Treatment in Advanced Solid Tumors — Jason J. Luke, MD
- First Human Study of TUB-030 for Patients with Advanced Solid Tumors — Tubulis GmbH
- First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations — Scorpion Therapeutics, Inc.
- Study on Intravenous T3011 Alone and with Other Treatments for Advanced Solid Tumors — ImmVira Pharma Co. Ltd
- Study on JAB-21822 for Adults with Advanced Solid Tumors with KRAS G12C Mutation — Jacobio Pharmaceuticals Co., Ltd.
- JAB-3312 Combination Therapy for Adults with Advanced Solid Tumors — Jacobio Pharmaceuticals Co., Ltd.
- Lorlatinib Continuation Study — Pfizer
- Study on Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan for Metastatic Squamous Non-small Cell Lung Cancer — Merck Sharp & Dohme LLC
- Personalized Treatment After Chemoradiotherapy and Immunotherapy for Stage III Non-Small Cell Lung Cancer (NSCLC) — Maximilian Diehn
- Phase 1/2 Study of BDTX-1535 for Patients with Glioblastoma or Non-Small Cell Lung Cancer with EGFR Mutations — Black Diamond Therapeutics, Inc.
- Phase III Study of Dato-DXd with Durvalumab and Carboplatin for Advanced Non-Small Cell Lung Cancer (NSCLC) Without Specific Genetic Changes — AstraZeneca
- Study on the Safety and Effectiveness of CJRB-101 with Pembrolizumab for Advanced or Metastatic Cancer — CJ Bioscience, Inc.
- Study of Oral MRT-2359 in Selected Cancer Patients — Monte Rosa Therapeutics, Inc
- Study on RP1 Alone and Combined with Nivolumab for Advanced Solid Tumors — Replimune Inc.
- Study on PC14586 for Patients with Advanced Solid Tumors with a TP53 Y220C Mutation (PYNNACLE) — PMV Pharmaceuticals, Inc
- Treating Early-stage Non-Small Cell Lung Cancer with Durvalumab and Radiation Therapy — Memorial Sloan Kettering Cancer Center
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as NSCLC to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.